-
Founded in:
2000-06-26 -
Country:
China -
Address:
No. 1, Xianyao Road, Xianju County, Taizhou City, Zhejiang Province -
Tax NO.:
913300007047892221 -
Registered Funds:
989.204866 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gentamicin sulfate |
It has antibacterial effects on various Gram-negative bacteria, Gram-positive bacteria and Helicobacter pylori. Its mechanism of action is to inhibit the synthesis of bacterial proteins.
More
It has antibacterial effects on various Gram-negative bacteria, Gram-positive bacteria and Helicobacter pylori. Its mechanism of action is to inhibit the synthesis of bacterial proteins. |
20mg | 1405-41-0 | 29 |
| Procaine hydrochloride |
It has a local anesthetic effect. Its mechanism of action is to competitively bind to the nerve membrane lipoprotein, block sodium ions, and hinder the conduction of nerve fibers.
More
It has a local anesthetic effect. Its mechanism of action is to competitively bind to the nerve membrane lipoprotein, block sodium ions, and hinder the conduction of nerve fibers. |
0.1g | 51-05-8 | 11 |
| Vitamin B12 |
It is a substance necessary for the formation of normal epithelial cells in the digestive tract
More
It is a substance necessary for the formation of normal epithelial cells in the digestive tract |
0.02mg | 68-19-9 | 16 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Flumazenil |
Benzodiazepine receptor antagonists, which competitively inhibit the reaction of benzodiazepines with their receptors, thereby specifically blocking their central nervous system effects.
More
Benzodiazepine receptor antagonists, which competitively inhibit the reaction of benzodiazepines with their receptors, thereby specifically blocking their central nervous system effects. |
78755-81-4 | 21 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cisatracurium besylate |
Cisatracurium besylate is a moderately effective, non-depolarizing skeletal muscle relaxant with an isoquinolinium benzyl ester structure. It binds to cholinergic receptors on the motor end plate to antagonize the effects of acetylcholine, thereby producing a competitive neuromuscular conduction blockade. This effect is easily antagonized by anticholinesterase drugs such as neostigmine or edrophonium. Human clinical studies have shown that this product is not associated with dose-dependent histamine release, even at doses as high as 8 times the ED95.
More
Cisatracurium besylate is a moderately effective, non-depolarizing skeletal muscle relaxant with an isoquinolinium benzyl ester structure. It binds to cholinergic receptors on the motor end plate to antagonize the effects of acetylcholine, thereby producing a competitive neuromuscular conduction blockade. This effect is easily antagonized by anticholinesterase drugs such as neostigmine or edrophonium. Human clinical studies have shown that this product is not associated with dose-dependent histamine release, even at doses as high as 8 times the ED95. |
96946-42-8 | 26 | |
| (1R,1R,2R,2R)-2,2-(3,11-dioxo-4,10-dioxa-1,13-tridecylene)bis[6,7-dimethoxy-1-(3,4-dimethoxybenzyl)-2-methyl |
Cisatracurium besylate is a neuromuscular blocker, a moderately effective, non-depolarizing skeletal muscle relaxant with an isoquinolinium benzyl ester structure. It binds to cholinergic receptors on the motor end plate to antagonize the effects of acetylcholine, thereby producing a competitive neuromuscular conduction blockade. This effect is easily antagonized by anticholinesterase drugs such as neostigmine or edrophonium. Human clinical studies have shown that this product is not associated with dose-dependent histamine release, even at doses as high as 8 times the ED95.
More
Cisatracurium besylate is a neuromuscular blocker, a moderately effective, non-depolarizing skeletal muscle relaxant with an isoquinolinium benzyl ester structure. It binds to cholinergic receptors on the motor end plate to antagonize the effects of acetylcholine, thereby producing a competitive neuromuscular conduction blockade. This effect is easily antagonized by anticholinesterase drugs such as neostigmine or edrophonium. Human clinical studies have shown that this product is not associated with dose-dependent histamine release, even at doses as high as 8 times the ED95. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Meloxicam |
This product is an enolic acid nonsteroidal anti-inflammatory drug (NSAID) with strong anti-inflammatory, analgesic and antipyretic effects. It can inhibit the synthesis of prostaglandins and selectively inhibit cyclooxygenase-2 (COX-2), making it safer than other NSAIDs.
More
This product is an enolic acid nonsteroidal anti-inflammatory drug (NSAID) with strong anti-inflammatory, analgesic and antipyretic effects. It can inhibit the synthesis of prostaglandins and selectively inhibit cyclooxygenase-2 (COX-2), making it safer than other NSAIDs. |
71125-38-7 | 56 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Rocuronium bromide |
A rapidly acting, intermediate-duration nondepolarizing neuromuscular blocking agent that acts by competitively binding to N-type acetylcholine receptors at the motor endplate; its action can be antagonized by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
More
A rapidly acting, intermediate-duration nondepolarizing neuromuscular blocking agent that acts by competitively binding to N-type acetylcholine receptors at the motor endplate; its action can be antagonized by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine. |
119302-91-9 | 30 |